ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0559

JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Signaling Cascade in Minor Salivary Gland Mesenchymal Stromal Cells
Abstract Number: 0560

IL-17 Regulates Apolipoprotein E in Lymph Node Stromal Cells During Infection and Autoimmunity
Abstract Number: 0561

CD8 T-Cell Expansion May Compensate for Natural Killer Cell Dysfunction in Mice with Chronic Excess IL-18
Abstract Number: 0562

Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D
Abstract Number: 0563

High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
Abstract Number: 0564

Identifying Shared Genetic Architecture Between RA and Other Conditions: A Phenome-Wide Association Study
Abstract Number: 0565

Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics
Abstract Number: 0566

SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children
Abstract Number: 0567

Gain-of-Function Mutations in Lyn Kinase Cause a Novel Autoinflammatory Disease with Small Vessel Vasculitis and Liver Fibrosis
Abstract Number: 0568

The Absence of Blk Leads to Increased Inflammation in a Murine Model of Kawasaki Disease
Abstract Number: 0569

Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation
Abstract Number: 0570

Clarifying Misbeliefs About Hydroxychloroquine (HCQ): Developing an Evidence-Based HCQ Benefits vs. Risk Decision Aid (HCQ-SAFE) Per Low Health Literacy Standards
Abstract Number: 0571

National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Abstract Number: 0572

ACR Workgroup to Develop Recommendations for PRO Use in Clinical Care for SLE
Abstract Number: 0573

Telehealth versus Outpatients Clinic Follow up in Rheumatoid Arthritis Patients a Randomized Controlled Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].